MENSSANA RESEARCH, INC.

Medtech · Private

BreathLink breath test that detects biomarkers of breast cancer from exhaled breath

Claim this profile

Follows are private to you and power your alerts

Updated

Sector
Medtech
Total capital
$2.4M
Federal grants
$2.4M
4 awards · 2015–2018
Rank in peer group#94 of 112
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
None on recordNo federal contract awards found.
Granted patents
0
1 pending

Capital timeline

2015201620172018FEDERAL ↑EQUITY ↓Cumulative $2.4M$231K$1.1M$920K$225K
2015201620172018FEDERAL ↑EQUITY ↓Cumulative $2.4M$231K$1.1M$920K$225K

Latest events

  • Federal grantHealth and Human S · Phase II · Validation of a rapid point-of-care breath test for breast cancer$225K
  • Federal grantHealth and Human S · Phase II · Validation of a rapid point-of-care breath test for breast cancer$920K
  • Federal grantHealth and Human S · Phase II · Validation of a rapid point-of-care breath test for breast cancer$1.1M
  • Federal grantHealth and Human S · Phase I · Validation of Point-of-Care Breath Test for Pulmonary TB$231K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 112 peers

Line = median

Medtech · Instrument

  • Federal grantsBelow median
  • Linked publications#1 · top 1%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 0 granted of 1
  • PendingSystem And Method For Remote Collection And Analysis Of Volatile Organic Components In BreathUSPTOApplication PCTUS2013029508

Recent research by its founders

  • Inhibition of the Caveolin-1 pathway promotes apoptosis and overcomes pan-tyrosine kinase inhibitor resistance in hepatocellular carcinoma202511 cites
  • 180 Optimal Neurosurgical Surgical Site Preparation: A Prospective Single-Center Study20250 cites
  • Incorporating Data Exploration in a “Lecture” Based Oceanography Course20250 cites

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .